Cytosorbents (NASDAQ:CTSO) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a report issued on Wednesday,Benzinga reports. They currently have a $10.00 target price on the medical research company’s stock.

Other equities research analysts have also issued reports about the company. Wall Street Zen started coverage on Cytosorbents in a research note on Wednesday, May 21st. They issued a “hold” rating for the company. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research note on Thursday, May 15th.

Cytosorbents Price Performance

Cytosorbents stock opened at $1.20 on Wednesday. The stock has a market cap of $75.13 million, a PE ratio of -4.29 and a beta of 1.05. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.30 and a current ratio of 2.61. Cytosorbents has a one year low of $0.70 and a one year high of $1.61. The stock has a fifty day moving average of $1.00 and a 200 day moving average of $1.01.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The business had revenue of $8.73 million during the quarter, compared to analysts’ expectations of $9.01 million. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. As a group, sell-side analysts predict that Cytosorbents will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors have recently modified their holdings of CTSO. Avenir Corp lifted its stake in shares of Cytosorbents by 63.1% in the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company’s stock valued at $5,045,000 after purchasing an additional 1,950,972 shares during the last quarter. CM Management LLC lifted its stake in shares of Cytosorbents by 36.3% during the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company’s stock worth $954,000 after acquiring an additional 254,076 shares during the last quarter. Skylands Capital LLC lifted its stake in shares of Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company’s stock worth $3,003,000 after acquiring an additional 221,080 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Key Client Fiduciary Advisors LLC lifted its stake in shares of Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock worth $78,000 after acquiring an additional 43,900 shares during the last quarter. 32.87% of the stock is owned by institutional investors.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.